Pfizer and BioNTech's, COVID-19 Vaccine to Be , Submitted for Emergency Authorization.
The vaccine created by the companies
is known as BNT162b2.
It is the first coronavirus
vaccine to be submitted
for approval by the Food and
Drug Administration (FDA). .
Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world, Albert Bourla, Pfizer CEO, via CNN.
The phase three trial of the vaccine commenced in July
and had more than 43,000 participants.
The vaccine proved to
be 95 percent effective
with no safety concerns.
We now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential, Albert Bourla, Pfizer CEO, via CNN.
The FDA is expected to approve the vaccine,
which means it could be available for some
high-risk populations by the middle of December.
Wide-scale availability of
the vaccine is not expected
until sometime in 2021
